Background: Hepatocellular carcinoma (HCC) is the most common type of liver cancer and one of the leading causes of cancer-related death worldwide. Advanced HCC displays strong resistance to chemotherapy, and traditional chemotherapy drugs do not achieve satisfactory therapeutic efficacy. The delivery of therapeutic compounds to the target site is a major challenge in the treatment of many diseases. Objective: This study aims to evaluate activated charcoal nanoparticles as a drug delivery system for anticancer agents (Sorafenib and Doxorubicin) in Hepatocellular Cancer Stem Cells. Method: The percent efficiency of entrapment (% EE) of the doxorubicin and sorafenib entrapped onto the activated charcoal was obtained by determining the free doxorubicin and sorafenib concentration in the supernatant-prepared solutions. Then the characterizations of nanoparticles were formed by determination of the particle size distribution, zeta potential, and polydispersity index (PDI). The anticancer activity of activated Charcoal, Doxorubicin-ACNP, sorafenib-ACNP, free doxorubicin, and free sorafenib solutions was measured based on cell viability percentage in HepG2 cell lines (ATCC-CCL 75). In vitro RBC’s toxicity of Doxorubicin/sorafenib loaded charcoal was estimated by hemolysis percentage. Results: The synthesized Doxorubicin-ACNP and Sorafenib-ACNP were evaluated and their physiochemical properties were also examined. Essentially, the percent Efficiency of Entrapment (EE %) was found to be 87.5% and 82.66% for Doxorubicin-ACNP and Sorafenib-ACNP, respectively. The loading capacity was 34.78% and 24.31% for Doxorubicin-ACNP and Sorafenib-ACNP. Using the Dynamic Light scattering [DLS] for the determination of the hydrodynamic size and surface zeta potential, a narrow sample size distribution was obtained of (18, 68, and 190 nm for charcoal, 105, 255, and 712 nm for doxorubicin, and 91, 295, and 955 nm for sorafenib), respectively. A surface charge of ？13.2, ？15.6 and ？17 was obtained for charcoal, doxorubicin/charcoal, and sorafenib/charcoal nanoparticles. The cytotoxic activity of Doxorubicin-ACNP and Sorafenib-ACNP was evaluated in-vitro against HepG2 cell lines and it was observed that Drug loaded ACNP improved anticancer activity when compared to Doxorubicin or Sorafenib alone. Moreover, testing the toxicity potential of DOX-ACNP and Sorafenib-ACNP showed a significant reduction in the hemolysis of red blood cells when compared to Doxorubicin and Sorafenib alone. Conclusion: In conclusion,
References
[1]
Satou M., Tateishi, R., Yatomi, Y. and Koike, K. (2021) Artificial Intelligence in the Diagnosis and Management of Hepatocellular Carcinoma. Journal of Gastroenterology and Hepatology, 36, 551-560. https://doi.org/10.1111/jgh.15413
[2]
Kong, F., Ye, Q., Miao, X., Liu, X., Huang, S., Xiong, L., et al. (2021) Current Status of Sorafenib Nanoparticle Delivery Systems in the Treatment of Hepatocellular Carcinoma. Theranostics, 11, 5464-5490. https://doi.org/10.7150/thno.54822
[3]
Llovet, J.M., Kelley, R.K., Villanueva, A., Singal, A.G., Pikarsky, E., Roayaie, S., et al. (2021) Hepatocellular Carcinoma. Nature Reviews Disease Primers, 7, Article No. 6. https://doi.org/10.1038/s41572-020-00240-3
[4]
Yang, R., Zhou, Y., Wang, Y., Du, C. and Wu, Y. (2020) Trends in Cancer Incidence and Mortality Rates in the United States from 1975 to 2016. Annals of Translational Medicine, 8, 1671-1671. https://doi.org/10.21037/atm-20-7841
[5]
Rich, N.E., Yopp, A.C., Singal, A.G. and Murphy, C.C. (2020) Hepatocellular Carcinoma Incidence Is Decreasing among Younger Adults in the United States. Clinical Gastroenterology and Hepatology, 18, 242-248.E5. https://doi.org/10.1016/j.cgh.2019.04.043
[6]
Yang, J.D. and Heimbach, J.K. (2020) New Advances in the Diagnosis and Management of Hepatocellular Carcinoma. BMJ, 371, m3544. https://doi.org/10.1136/bmj.m3544
[7]
Kis, B., El-Haddad, G., Sheth, R.A., Parikh, N.S., Ganguli, S., Shyn, P.B., et al. (2017) Liver-Directed Therapies for Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma. Cancer Control, 24, 1-19. https://doi.org/10.1177/1073274817729244
[8]
Riccardi, F., Dal Bo, M., Macor, P. and Toffoli, G. (2023) A Comprehensive Overview on Antibody-Drug Conjugates: From the Conceptualization to Cancer Therapy. Frontiers in Pharmacology, 14, Article 1274088. https://doi.org/10.3389/fphar.2023.1274088
[9]
Ma, W., Zhang, X. and Zhuang, L. (2023) Exogenous Hydrogen Sulfide Induces A375 Melanoma Cell Apoptosis through Overactivation of the Unfolded Protein Response. Clinical, Cosmetic and Investigational Dermatology, 16, 1641-1651. https://doi.org/10.2147/ccid.s412588
[10]
Falzone, L., Bordonaro, R. and Libra, M. (2023) Snapshot: Cancer Chemotherapy. Cell, 186, 1816-1816.e1. https://doi.org/10.1016/j.cell.2023.02.038
[11]
Anand, U., Dey, A., Chandel, A.K.S., Sanyal, R., Mishra, A., Pandey, D.K., et al. (2023) Cancer Chemotherapy and Beyond: Current Status, Drug Candidates, Associated Risks and Progress in Targeted Therapeutics. Genes & Diseases, 10, 1367-1401. https://doi.org/10.1016/j.gendis.2022.02.007
[12]
Zhao, H., Yu, J., Zhang, R., Chen, P., Jiang, H. and Yu, W. (2023) Doxorubicin Prodrug-Based Nanomedicines for the Treatment of Cancer. European Journal of Medicinal Chemistry, 258, Article ID: 115612. https://doi.org/10.1016/j.ejmech.2023.115612
[13]
Yamada, Y. (2020) Dimerization of Doxorubicin Causes Its Precipitation. ACS Omega, 5, 33235-33241. https://doi.org/10.1021/acsomega.0c04925
[14]
Zhong, L., Li, Y., Xiong, L., Wang, W., Wu, M., Yuan, T., et al. (2021) Small Molecules in Targeted Cancer Therapy: Advances, Challenges, and Future Perspectives. Signal Transduction and Targeted Therapy, 6, Article No. 201. https://doi.org/10.1038/s41392-021-00572-w
[15]
Peng, F., Liao, M., Qin, R., Zhu, S., Peng, C., Fu, L., et al. (2022) Regulated Cell Death (RCD) in Cancer: Key Pathways and Targeted Therapies. Signal Transduction and Targeted Therapy, 7, Article No. 286. https://doi.org/10.1038/s41392-022-01110-y
[16]
Mansoori, B., Mohammadi, A., Davudian, S., Shirjang, S. and Baradaran, B. (2017) The Different Mechanisms of Cancer Drug Resistance: A Brief Review. Advanced Pharmaceutical Bulletin, 7, 339-348. https://doi.org/10.15171/apb.2017.041
[17]
Metkar, S.P., Fernandes, G., Navti, P.D., Nikam, A.N., Kudarha, R., Dhas, N., et al. (2023) Nanoparticle Drug Delivery Systems in Hepatocellular Carcinoma: A Focus on Targeting Strategies and Therapeutic Applications. OpenNano, 12, Article ID: 100159. https://doi.org/10.1016/j.onano.2023.100159
[18]
Lei, Y., He, X., Li, J. and Mo, C. (2024) Drug Resistance in Hepatocellular Carcinoma: Theoretical Basis and Therapeutic Aspects. Frontiers in Bioscience-Landmark, 29, Article 52. https://doi.org/10.31083/j.fbl2902052
[19]
Sangro, B., Sarobe, P., Hervás-Stubbs, S. and Melero, I. (2021) Advances in Immunotherapy for Hepatocellular Carcinoma. Nature Reviews Gastroenterology & Hepatology, 18, 525-543. https://doi.org/10.1038/s41575-021-00438-0
[20]
Adepu, S. and Ramakrishna, S. (2021) Controlled Drug Delivery Systems: Current Status and Future Directions. Molecules, 26, Article 5905. https://doi.org/10.3390/molecules26195905
[21]
Yu, L., Liu, S., Jia, S. and Xu, F. (2023) Emerging Frontiers in Drug Delivery with Special Focus on Novel Techniques for Targeted Therapies. Biomedicine & Pharmacotherapy, 165, Article ID: 115049. https://doi.org/10.1016/j.biopha.2023.115049
[22]
Edis, Z., Wang, J., Waqas, M.K., Ijaz, M. and Ijaz, M. (2021) Nanocarriers-Mediated Drug Delivery Systems for Anticancer Agents: An Overview and Perspectives. International Journal of Nanomedicine, 16, 1313-1330. https://doi.org/10.2147/ijn.s289443
[23]
Sun, L., Cai, Y., Liu, Y., Song, D., Liu, Y., Yao, H., et al. (2013) Activated Carbon Nanoparticles as Carriers of Anticancer Drugs. Nano Biomedicine and Engineering, 35, 94-101. https://doi.org/10.5101/nbe.v3i1.p94-101
[24]
Kapourani, A., Katopodis, K., Valkanioti, V., Chatzitheodoridou, M., Cholevas, C. and Barmpalexis, P. (2024) Evaluation of Suitable Polymeric Matrix/Carriers during Loading of Poorly Water Soluble Drugs onto Mesoporous Silica: Physical Stability and in Vitro Supersaturation. Polymers, 16, Article 802. https://doi.org/10.3390/polym16060802
[25]
Zhang, C., Duan, S., Guo, M., Yuan, Y., Huang, Z., Zhu, J., et al. (2020) Effects of CYP3A5 Polymorphisms on Efficacy and Safety of Tacrolimus Therapy in Patients with Idiopathic Membranous Nephropathy. Pharmacogenomics and Personalized Medicine, 13, 141-149. https://doi.org/10.2147/pgpm.s247892
[26]
Wang, Y., Li, F., Xin, J., Xu, J., Yu, G. and Shi, Q. (2023) Mesoporous Drug Delivery System: From Physical Properties of Drug in Solid State to Controlled Release. Molecules, 28, Article 3406. https://doi.org/10.3390/molecules28083406
[27]
Jjagwe, J., Olupot, P.W., Menya, E. and Kalibbala, H.M. (2021) Synthesis and Application of Granular Activated Carbon from Biomass Waste Materials for Water Treatment: A Review. Journal of Bioresources and Bioproducts, 6, 292-322. https://doi.org/10.1016/j.jobab.2021.03.003
[28]
Raut, H., Jadhav, C., Shetty, K., Laxane, N., Nijhawan, H.P., Rao, G.K., et al. (2022) Sorafenib Tosylate Novel Drug Delivery Systems: Implications of Nanotechnology in both Approved and Unapproved Indications. OpenNano, 8, Article ID: 100103. https://doi.org/10.1016/j.onano.2022.100103
[29]
Mossenta, M., Busato, D., Dal Bo, M., Macor, P. and Toffoli, G. (2022) Novel Nanotechnology Approaches to Overcome Drug Resistance in the Treatment of Hepatocellular Carcinoma: Glypican 3 as a Useful Target for Innovative Therapies. International Journal of Molecular Sciences, 23, Article ID: 10038. https://doi.org/10.3390/ijms231710038
[30]
Malarvizhi, G.L., Retnakumari, A.P., Nair, S. and Koyakutty, M. (2014) Transferrin Targeted Core-Shell Nanomedicine for Combinatorial Delivery of Doxorubicin and Sorafenib against Hepatocellular Carcinoma. Nanomedicine: Nanotechnology, Biology and Medicine, 10, 1649-1659. https://doi.org/10.1016/j.nano.2014.05.011
[31]
Yusuf, A., Almotairy, A.R.Z., Henidi, H., Alshehri, O.Y. and Aldughaim, M.S. (2023) Nanoparticles as Drug Delivery Systems: A Review of the Implication of Nanoparticles’ Physicochemical Properties on Responses in Biological Systems. Polymers, 15, Article 1596. https://doi.org/10.3390/polym15071596
[32]
Hsiao, C., Huang, H., Chen, Y., Chen, M. and Lin, Y. (2022) Enhanced Antitumor Effect of Doxorubicin through Active-Targeted Nanoparticles in Doxorubicin-Resistant Triple-Negative Breast Cancer. Journal of Drug Delivery Science and Technology, 77, Article ID: 103845. https://doi.org/10.1016/j.jddst.2022.103845
[33]
Lee, J., Choi, M. and Song, I. (2023) Recent Advances in Doxorubicin Formulation to Enhance Pharmacokinetics and Tumor Targeting. Pharmaceuticals, 16, Article 802. https://doi.org/10.3390/ph16060802
[34]
Liu, G., Yang, L., Chen, G., Xu, F., Yang, F., Yu, H., et al. (2021) A Review on Drug Delivery System for Tumor Therapy. Frontiers in Pharmacology, 12, Article 735446. https://doi.org/10.3389/fphar.2021.735446
[35]
Chehelgerdi, M., Chehelgerdi, M., Allela, O.Q.B., Pecho, R.D.C., Jayasankar, N., Rao, D.P., et al. (2023) Progressing Nanotechnology to Improve Targeted Cancer Treatment: Overcoming Hurdles in Its Clinical Implementation. Molecular Cancer, 22, Article No. 169. https://doi.org/10.1186/s12943-023-01865-0
[36]
Hameed, S.F. and Rushdi, S.A. (2019) Mass Transfer Coefficient Study for Unloading of Naproxen from Activated Carbon as Drug Delivery. Al-Qadisiyah Journal for Engineering Sciences, 12, 232-239. https://doi.org/10.30772/qjes.v12i4.619
[37]
Shamsa, E.S., Mahjub, R., Mansoorpour, M., Rafiee-Tehrani, M. and Abedin Dorkoosh, F. (2018) Nanoparticles Prepared from N, N-Dimethyl-N-Octyl Chitosan as the Novel Approach for Oral Delivery of Insulin: Preparation, Statistical Optimization and In-vitro Characterization. Iranian Journal of Pharmaceutical Research, 17, 442-459.
[38]
Zare, M., Mohammadi Samani, S. and Sobhani, Z. (2018) Enhanced Intestinal Permeation of Doxorubicin Using Chitosan Nanoparticles. Advanced Pharmaceutical Bulletin, 8, 411-417. https://doi.org/10.15171/apb.2018.048
[39]
Miriyala, N., Ouyang, D., Perrie, Y., Lowry, D. and Kirby, D.J. (2017) Activated Carbon as a Carrier for Amorphous Drug Delivery: Effect of Drug Characteristics and Carrier Wettability. European Journal of Pharmaceutics and Biopharmaceutics, 115, 197-205. https://doi.org/10.1016/j.ejpb.2017.03.002
[40]
El-Zeftawy, M. and Ghareeb, D. (2023) Pharmacological Bioactivity of Ceratonia Siliqua Pulp Extract: In Vitro Screening and Molecular Docking Analysis, Implication of Keap-1/nrf2/nf-ĸb Pathway. Scientific Reports, 13, Article No. 12209. https://doi.org/10.1038/s41598-023-39034-4
[41]
Sæbø, I., Bjørås, M., Franzyk, H., Helgesen, E. and Booth, J. (2023) Optimization of the Hemolysis Assay for the Assessment of Cytotoxicity. International Journal of Molecular Sciences, 24, Article 2914. https://doi.org/10.3390/ijms24032914
[42]
Jain, A.K. and Thareja, S. (2019) InVitro and in Vivo Characterization of Pharmaceutical Nanocarriers Used for Drug Delivery. Artificial Cells,Nanomedicine, and Biotechnology, 47, 524-539. https://doi.org/10.1080/21691401.2018.1561457
[43]
Berbel Manaia, E., Paiva Abuçafy, M., Chiari-Andréo, B.G., Lallo Silva, B., Oshiro-Júnior, J.A. and Chiavacci, L. (2017) Physicochemical Characterization of Drug Nanocarriers. International Journal of Nanomedicine, 12, 4991-5011. https://doi.org/10.2147/ijn.s133832
[44]
Babos, G., Biró, E., Meiczinger, M. and Feczkó, T. (2018) Dual Drug Delivery of Sorafenib and Doxorubicin from PLGA and PEG-PLGA Polymeric Nanoparticles. Polymers, 10, Article 895. https://doi.org/10.3390/polym10080895
[45]
Farasati Far, B., Naimi-Jamal, M.R., Daneshgar, H. and Rabiee, N. (2023) Co-delivery of Doxorubicin/sorafenib by Dna-Decorated Green Zif-67-Based Nanocarriers for Chemotherapy and Hepatocellular Carcinoma Treatment. Environmental Research, 225, Article ID: 115589. https://doi.org/10.1016/j.envres.2023.115589
[46]
Babos, G., Rydz, J., Kawalec, M., Klim, M., Fodor-Kardos, A., Trif, L., et al. (2020) Poly(3-hydroxybutyrate)-based Nanoparticles for Sorafenib and Doxorubicin Anticancer Drug Delivery. International Journal of Molecular Sciences, 21, Article 7312. https://doi.org/10.3390/ijms21197312
[47]
Maeda, H. (2021) The 35th Anniversary of the Discovery of EPR Effect: A New Wave of Nanomedicines for Tumor-Targeted Drug Delivery—Personal Remarks and Future Prospects. Journal of Personalized Medicine, 11, Article 229. https://doi.org/10.3390/jpm11030229
[48]
Ruman, U., et al. (2021) Sorafenib and 5-Fluorouracil Loaded Dual Drug Nanodelivery Systems for Hepatocellular Carcinoma and Colorectal Adenocarcinoma. https://doi.org/10.21203/rs.3.rs-152602/v1
[49]
Li, C., Guan, H., Li, Z., Wang, F., Wu, J. and Zhang, B. (2020) Study on Different Particle Sizes of Dox-Loaded Mixed Micelles for Cancer Therapy. Colloids and Surfaces B:Biointerfaces, 196, Article ID: 111303. https://doi.org/10.1016/j.colsurfb.2020.111303
[50]
Davis, M.E., Chen, Z. and Shin, D.M. (2008) Nanoparticle Therapeutics: An Emerging Treatment Modality for Cancer. Nature Reviews Drug Discovery, 7, 771-782. https://doi.org/10.1038/nrd2614
[51]
Fan, D., Cao, Y., Cao, M., Wang, Y., Cao, Y. and Gong, T. (2023) Nanomedicine in Cancer Therapy. Signal Transduction and Targeted Therapy, 8, Article No. 293. https://doi.org/10.1038/s41392-023-01536-y
[52]
Fang, J., Islam, W. and Maeda, H. (2020) Exploiting the Dynamics of the EPR Effect and Strategies to Improve the Therapeutic Effects of Nanomedicines by Using EPR Effect Enhancers. Advanced Drug Delivery Reviews, 157, 142-160. https://doi.org/10.1016/j.addr.2020.06.005
[53]
Bhattacharjee, S. (2016) DLS and Zeta Potential—What They Are and What They Are Not? Journal of Controlled Release, 235, 337-351. https://doi.org/10.1016/j.jconrel.2016.06.017
[54]
Carvalho, P.M., Felício, M.R., Santos, N.C., Gonçalves, S. and Domingues, M.M. (2018) Application of Light Scattering Techniques to Nanoparticle Characterization and Development. Frontiers in Chemistry, 6, Article 237. https://doi.org/10.3389/fchem.2018.00237
